Accelerating Precision Oncology Worldwide
Clinical and Research Laboratories
At NuProbe, we are developing innovative assays to accelerate cancer research. Our products allow laboratories to detect and quantify low-abundant variants across multiple platforms from both cell-free DNA and tissue specimens. Contact us today to learn more.
We provide assay development and testing services to support all stages of biomarker detection programs. Our flexible platform utilizes proprietary technologies to deliver best-in-class sensitivity from solid tumor and liquid biopsy. Contact one of our experts today to find out what NuProbe can do for you.
News & Press Releases
SADDLE approach uses computational primer design to minimize primer-dimer formation, and thus does not require enzymatic primers and primer-dimer removal.
The results show detection of CNVs down to 5% heterozygous single copy gain or loss, and mutations down to 0.1% variant allele frequency (VAF), from both formalin-fixed, paraffin-embedded (FFPE) tissue samples and from cell-free DNA (cfDNA) samples1.
SEPT 26-29, 2022
World CB & CDx
NOV 01-05, 2022
AMP Annual Meeting
DEC 10-13, 2022
ASH Annual Meeting